Asset Management One Co. Ltd. Has $7.43 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Asset Management One Co. Ltd. lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 4.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,185 shares of the company's stock after selling 3,246 shares during the period. Asset Management One Co. Ltd. owned 0.07% of Neurocrine Biosciences worth $7,431,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in NBIX. Huntington National Bank boosted its holdings in shares of Neurocrine Biosciences by 73.5% during the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after acquiring an additional 97 shares in the last quarter. GeoWealth Management LLC boosted its stake in shares of Neurocrine Biosciences by 65.4% during the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company's stock valued at $35,000 after purchasing an additional 102 shares in the last quarter. Lindbrook Capital LLC boosted its position in Neurocrine Biosciences by 53.5% during the 4th quarter. Lindbrook Capital LLC now owns 373 shares of the company's stock worth $51,000 after buying an additional 130 shares during the period. Versant Capital Management Inc lifted its holdings in shares of Neurocrine Biosciences by 404.9% during the first quarter. Versant Capital Management Inc now owns 409 shares of the company's stock worth $45,000 after purchasing an additional 328 shares during the period. Finally, Harbor Capital Advisors Inc. acquired a new position in shares of Neurocrine Biosciences during the first quarter worth $48,000. Institutional investors and hedge funds own 92.59% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have commented on NBIX. Piper Sandler reaffirmed an "overweight" rating and set a $154.00 target price (down from $160.00) on shares of Neurocrine Biosciences in a report on Tuesday, May 6th. BMO Capital Markets lifted their price objective on Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a research note on Tuesday, May 6th. Morgan Stanley reaffirmed an "overweight" rating and issued a $150.00 price objective (down from $185.00) on shares of Neurocrine Biosciences in a research note on Friday, March 7th. Wedbush restated an "outperform" rating on shares of Neurocrine Biosciences in a research report on Tuesday, May 6th. Finally, Evercore ISI dropped their price target on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Three equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $162.00.

Insider Transactions at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 9,613 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $120.38, for a total value of $1,157,212.94. Following the completion of the transaction, the director now owns 514,596 shares in the company, valued at $61,947,066.48. This trade represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William H. Rastetter sold 30,000 shares of Neurocrine Biosciences stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the completion of the transaction, the director now owns 37,491 shares of the company's stock, valued at $4,131,508.20. The trade was a 44.45% decrease in their position. The disclosure for this sale can be found here. 4.80% of the stock is currently owned by company insiders.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $125.42 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $157.98. The firm has a market cap of $12.41 billion, a PE ratio of 42.52, a P/E/G ratio of 1.30 and a beta of 0.24. The stock has a fifty day moving average price of $118.87 and a 200-day moving average price of $121.88.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The company had revenue of $572.60 million for the quarter, compared to analysts' expectations of $587.06 million. During the same quarter in the previous year, the business earned $1.20 EPS. The company's revenue for the quarter was up 11.1% on a year-over-year basis. As a group, equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.